# Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)

> **NCT07286747** · PHASE2 · RECRUITING · sponsor: **University Hospital Schleswig-Holstein** · enrollment: 390 (estimated)

## Conditions studied

- Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)

## Interventions

- **DRUG:** controlled-ileal-release nicotinic acid as multiple dose 100 mg/day
- **DRUG:** controlled-ileal-release nicotinic acid as multiple dose 200 mg/day
- **DRUG:** controlled-ileal-release nicotinic acid as multiple dose placebo

## Key facts

- **NCT ID:** NCT07286747
- **Lead sponsor:** University Hospital Schleswig-Holstein
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-03
- **Primary completion:** 2028-05-01
- **Final completion:** 2028-12-31
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07286747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07286747, "Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07286747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*